| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 08/12/2010 | US20100203039 3-aminocyclopentanecarboxamides as modulators of chemokine receptors |
| 08/12/2010 | US20100203038 Methods of using gpr119 to identify compounds useful for increasing bone mass in an individual |
| 08/12/2010 | US20100203037 identifying a Glucose-dependent Insulinotropic Peptide (GIP) secretagogue; G protein-coupled receptor (GPCR); useful as therapeutic agents for treating or preventing a condition characterized by low bone mass, such as osteoporosis |
| 08/12/2010 | US20100203036 Targets for tumor growth inhibition |
| 08/12/2010 | US20100203035 B7-h3 in cancer |
| 08/12/2010 | US20100203032 Orlistat compositions |
| 08/12/2010 | US20100203031 Method for enhancing the cleavage activity of i-crei derived meganucleases |
| 08/12/2010 | US20100203027 Viral vector for gene therapy |
| 08/12/2010 | US20100203020 Methods of generating, repairing and/or maintaining connective tissue in vivo |
| 08/12/2010 | US20100203017 Cladribine Regimen for Treating Multiple Sclerosis |
| 08/12/2010 | US20100203016 Pregnancy hormone combination for treatment of autoimmune diseases |
| 08/12/2010 | US20100203015 Carba-nucleoside analogs for antiviral treatment |
| 08/12/2010 | US20100203013 Treating Hepatitis C Virus Infection |
| 08/12/2010 | US20100203012 Iap bir domain binding compounds |
| 08/12/2010 | US20100203009 Pathway for Th-17 Cell Development and Methods Utilizing Same |
| 08/12/2010 | US20100203007 Novel benzodiazepine derivatives |
| 08/12/2010 | US20100203006 Devolatilization apparatus and process |
| 08/12/2010 | US20100203005 Transdermal compositions |
| 08/12/2010 | US20100203004 Cosmetic composition containing a tensioning agent and an acrylic polymer |
| 08/12/2010 | US20100203001 Process for forming disulfide bridges |
| 08/12/2010 | US20100202989 Methods for treatment of dermatological conditions |
| 08/12/2010 | US20100202986 Compositions For Delivering A Drug |
| 08/12/2010 | US20100202984 Naphthalene amidine imides |
| 08/12/2010 | US20100202979 Compositions and methods for treatment of pulmonary diseases and conditions |
| 08/12/2010 | US20100202977 Modulation of Stat 6 Expression for the Treatment of Airway Hyperresponsiveness |
| 08/12/2010 | US20100202973 Microrna molecules associated with inflammatory skin disorders |
| 08/12/2010 | US20100202971 Compound having tumor-resident property |
| 08/12/2010 | US20100202969 Nanoparticles for imaging and treating chlamydial infection |
| 08/12/2010 | US20100202968 Method of Providing Disease-Specific Binding Molecules and Targets |
| 08/12/2010 | US20100202963 Therapies for hematologic malignancies |
| 08/12/2010 | US20100200066 Methods and intermediates for the synthesis of dipyrrin-substituted porphyrinic macrocycles |
| 08/12/2010 | DE102009008256A1 Prodrugs vom Typ N-hydroxylierter Amidine, Guanidine und/oder Aminohydrazone zur Applikation über die Haut Prodrugs of type N-hydroxylated amidines, guanidines and / or Aminohydrazone for application on the skin |
| 08/12/2010 | DE102009007997A1 New nitrogen-containing compounds useful e.g. as a repellent for resistance and/or deterrence of arthropods e.g. mosquitoes, horseflies fleas, lice, ticks, mites and ants in cosmetic and/or dermatological formulations |
| 08/12/2010 | DE102009007929A1 Use of L-ribozymes (which are capable of splitting L-RNA in a region of a target sequence) for preparing composition to treat undesired physiological secondary reactions due to administration of a therapeutic molecule containing L-RNA |
| 08/12/2010 | DE102009007853A1 Mit Alkylphosphocholinen behandelte Intraokularlinsen zur pharmakologischen Nachstarprophylaxe Treated with alkylphosphocholines intraocular lenses for the pharmacological Nachstarprophylaxe |
| 08/12/2010 | CA2761389A1 Novel prodrugs of steroidal cyp17 inhibitors/antiandrogens |
| 08/12/2010 | CA2751987A1 Design, synthesis and evaluation of procaspase activating compounds as personalized anti-cancer drugs |
| 08/12/2010 | CA2751695A1 Aminopyrazine derivatives and medicines |
| 08/12/2010 | CA2751638A1 Medicinal use of 5-benzylaminosalicylic acid derivative or its salt |
| 08/12/2010 | CA2751565A1 Pyridazinone compounds |
| 08/12/2010 | CA2751563A1 Methods of inhibiting fibrogenesis and treating fibrotic disease |
| 08/12/2010 | CA2751539A1 Derivatives of 6-(6-nh-substituted-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors |
| 08/12/2010 | CA2751536A1 Indoline derivatives |
| 08/12/2010 | CA2751535A1 Substituted spiro-amides as b1r modulators |
| 08/12/2010 | CA2751525A1 Derivatives of 6-(6-o-cycloalkyl or 6-nh-cycloalkyl-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors |
| 08/12/2010 | CA2751495A1 Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof |
| 08/12/2010 | CA2751494A1 Benzoic acid (1-phenyl-2-pyridin-4-yl) ethyl esters as phosphodiesterase inhibitors |
| 08/12/2010 | CA2751489A1 Dual targeting of mir-208 and mir-499 in the treatment of cardiac disorders |
| 08/12/2010 | CA2751481A1 Derivatives of azaspiranyl-alkylcarbamates of 5-member heterocyclic compounds, preparation thereof and therapeutic use thereof |
| 08/12/2010 | CA2751474A1 Derivatives of 6-(6-substituted-triazolopyridazine-sulfanyl) 5-fluoro-benzothiazoles and 5-fluoro-benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as metinhibitors |
| 08/12/2010 | CA2751458A1 Purine nucleoside monophosphate prodrugs for treatment of cancer and viral infections |
| 08/12/2010 | CA2751443A1 Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma |
| 08/12/2010 | CA2751412A1 Methods of reducing the proliferation and viability of microbial agents |
| 08/12/2010 | CA2751402A1 Substituted indole compounds as bradykinin receptor 1 modulators |
| 08/12/2010 | CA2751399A1 Buccal application system comprising 17a-estradiol |
| 08/12/2010 | CA2751397A1 Treatment of lung cancer with a parp inhibitor in combination with a growth factor inhibitor |
| 08/12/2010 | CA2751392A1 Crystalline form of r)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5-hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
| 08/12/2010 | CA2751386A1 Bismuth-thiols as antiseptics for epithelial tissues, acute and chronic wounds, bacterial biofilms and other indications |
| 08/12/2010 | CA2751313A1 Process for the preparation of a pharmaceutical composition comprising ezetimibe |
| 08/12/2010 | CA2751304A1 Hesperidin-containing composition |
| 08/12/2010 | CA2751270A1 Pharmaceutical grade phthalazinediones, process for their preparation and pharmaceutical compositions containing them |
| 08/12/2010 | CA2751263A1 Novel saponin compounds, methods of preparation thereof, use thereof and pharmaceutical compositions |
| 08/12/2010 | CA2751141A1 Inhibitors of jun n-terminal kinase |
| 08/12/2010 | CA2751039A1 Pharmaceutical composition for oral administration |
| 08/12/2010 | CA2750935A1 Heteroaryls and their use as pi3k inhibitors |
| 08/12/2010 | CA2750875A1 Derivatives of 6-(6-o-substituted-triazolopyridazine-sulfanyl) benzothiazoles and benzimidazoles, preparation thereof, use thereof as drugs, and use thereof as met inhibitors |
| 08/12/2010 | CA2750844A1 Triptolide c-ring derivatives as anticancer agents and immune modulators |
| 08/12/2010 | CA2750714A1 Dihydroquinolinone derivatives |
| 08/12/2010 | CA2750704A1 Phenylimidazole compounds |
| 08/12/2010 | CA2750611A1 Chronotherapeutic pharmaceutical composition |
| 08/12/2010 | CA2750519A1 Novel benzodiazepine derivatives |
| 08/12/2010 | CA2750517A1 Cyclic inhibitors of 11beta-hydroxysteroid dehydrogenase 1 |
| 08/12/2010 | CA2750089A1 Novel method for the synthesis of ivabradine and the pharmaceutically acceptable acid addition salts thereof |
| 08/12/2010 | CA2749933A1 Formulations of desvenlafaxine |
| 08/12/2010 | CA2749856A1 Isoxazole-3-carboxamide derivatives |
| 08/12/2010 | CA2749837A1 Derivatives of n2-(3-pyridil or phenyl) -n4- (4-piperidyl) -2,4- pyrimidinediamine useful in the treatment of inflammatory, autoimmune or proliferative diseases |
| 08/12/2010 | CA2749677A1 Isoxazole-5-carboxamide derivatives |
| 08/12/2010 | CA2749358A1 A novel cyanopyrimidine derivative |
| 08/12/2010 | CA2749309A1 Pyrrolidine triple reuptake inhibitors |
| 08/12/2010 | CA2749209A1 Indole derivatives as anticancer agents |
| 08/12/2010 | CA2748943A1 Pyrrolopyrimidinyl axl kinase inhibitors |
| 08/12/2010 | CA2748862A1 Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators |
| 08/12/2010 | CA2744946A1 Cyclic inhibitors of 11.beta.-hydroxysteroid dehydrogenase 1 |
| 08/12/2010 | CA2741052A1 Pharmaceutical compositions comprising imidazoquinolin(amines) and derivatives thereof suitable for local administration |
| 08/12/2010 | CA2724152A1 Solid state forms of aliskiren compounds |
| 08/11/2010 | EP2216343A1 Human monoclonal antibody against a costimulatory signal transduction molecule AILIM and pharmaceutical use thereof |
| 08/11/2010 | EP2216335A1 Tetriacyclodipyranyl coumarins and the anti-hiv and anti-tuberculosis uses thereof |
| 08/11/2010 | EP2216334A1 Hiv protease inhibiting sulfonamides |
| 08/11/2010 | EP2216330A1 Oxadiazolidinedione compound |
| 08/11/2010 | EP2216329A1 Processes for the preparation of tadalafi |
| 08/11/2010 | EP2216327A1 Benzoic acid (1-phenyl-2-pyridin-4-yl)ethyl esters as phosphodiesterase inhibitors |
| 08/11/2010 | EP2216323A2 Methods for synthesizing and purifying aminoalkyl tetracycline compounds |
| 08/11/2010 | EP2216319A2 Oligomers of straight-chain and unbranched fatty acids, and medicaments containing the same |
| 08/11/2010 | EP2216318A2 Resolvins: Biotemplates for therapeutic interventions |
| 08/11/2010 | EP2216073A1 Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| 08/11/2010 | EP2216047A1 Regulator for signaling of toll-like receptor, which comprises cathepsin inhibitor as active ingredient |
| 08/11/2010 | EP2216037A1 Periodontal bacterial growth inhibitor, oral hygiene product, and food and drink |
| 08/11/2010 | EP2216031A1 Buffered Compositions for dialysis |
| 08/11/2010 | EP2216030A1 Prevention of in-stent thrombosis and complications after arterial angioplasty with stent placement using magnesium |
| 08/11/2010 | EP2216029A2 Oligonucleotides for treatment of prostate and other cancers |